Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

La_Parka3 Sep. 23 at 2:48 AM

$MRNA $PFE Imagine shorting a biotech stock but all they know is MAHA, nonsensical buzzwords, and conspiratorial concepts that aren’t even connected to the sector.

0 · Reply

cmhuff Sep. 23 at 12:25 AM

$PFE Pretty happy here. Holding well enough, paying a nice dividend, and selling covered calls above my average for a few extra percent.

0 · Reply

DefenseMania Sep. 22 at 11:09 PM

$AMGN buying this at .34 in 1989 !!! $NVS $GILD $PFE

0 · Reply

mr_kO1 Sep. 22 at 6:30 PM

$PFE $PFE 🆙 80%

0 · Reply

bullman_is_back Sep. 22 at 5:41 PM

$VKTX $PFE takeout candidate?!

2 · Reply

SellasgpsCurativeBAT11 Sep. 22 at 4:10 PM

$AZN $JNJ $PFE $SLS GPS An off-the-shelf injection that reprograms immunity itself with 0 Toxicity, 0 Major Adverse Reactions, 0 safety issues. Same day Outpatient treatment for one of the most lethal cancers and patients get to go home same day. Shorts are being Reckless here. They see a small biotech with a peptide vaccine. They don't understand the biology. They haven't read the data. And that ignorance is going to cost them everything. The real breakthrough is dual MHC Class I and Class II activation. Multivalency also ensures the cancer can't run. Together, they create a self-sustaining, polyclonal, living defense system inside the patient, one that hunts WT1-expressing cells for the rest of their life. And the 80% GPS responders? They aren't likely just surviving. They are functionally cured. Not managed. Not in fragile remission. CURED. With infinite dosing their T cells are still patrolling YEARS later. No cytokine storms. No need for a donor search. ✌️🙏❤️‍🩹

0 · Reply

truthseeeker Sep. 22 at 4:10 PM

$PFE Do you not find it interesting the level of total nonsense we see posted on these boards. How about the one by a poster saying that there is a big conspiratorial push by govt's and other entities to punish shorts on PFE! THAT IS COMPLETELY NONSENSE and NOT TRUTH! It is ridiculous on so many levels but here is one simple truth that belies the whole silliness- that is there is not even a large short position on PFE. No significant positions to squeeze! What utter nonsense!

1 · Reply

SellasgpsCurativeBAT11 Sep. 22 at 4:01 PM

$ABBV $SLS $JNJ $AZN $PFE Rob Excellent post. I like to add GPS Ad Infinitum Dosage administration of 3 year plus was made public over a year ago. Sellas GPS Ad Infinitum Dosage has now surpassed 4 year mark. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Sep. 22 at 3:51 PM

$SLS $JNJ $PFE $AZN Longs We all know by now there are multiple big pharmaceuticals on the table right now, that have formally made offers contingent on Regal Pivotal Registrational Phase 3 study Breakthrough data. Any time a company enters into a formal M&A discussion, a QP is automatic. Until Sellas BOD determines that an offer is adequateThere is no requirement to notify shareholders. « $SLS has COC in place earlier this year with golden parachutes for top executives. 0 insider sells in Sellas Corporate history other than tax purposes. My # 1 pick for suitor is $JNJ and won’t be surprised if a deal is consummated pre data. All things are possible here, but you have to be in it before T1 halt or watch PPS shoot in to triple digits after the trading halt is lifted. GPS Regal is already extraordinary to date for a big pharmaceutical to make a move because after Regal Phase 3 data there will be a bidding war. ✌️🙏❤️‍🩹

0 · Reply

sam92 Sep. 22 at 3:24 PM

$PFE $SPSIPH $DJUSPR PFE Finally well deserved turnaround starting ! $ $ $ $ $ $ $ $ https://www.tradingview.com/chart/bor9VVk1/?symbol=NASDAQ%3AGRML

0 · Reply

Pfizer CEO Bourla plans to attend White House state dinner for China's Xi, source says

Sep 22, 2026, 10:00 AM EDT - 13 hours ago

Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts

Sep 22, 2026, 6:50 AM EDT - 16 hours ago

Pfizer Transcript: U.S. All Stars Conference

Sep 21, 2026, 5:41 PM EDT - 1 day ago

Pharmaceutical Companies Push Trump Administration to Protect China Deals

LLY MRK

Sep 15, 2026, 10:00 AM EDT - 7 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Sep 14, 2026, 10:45 AM EDT - 8 days ago

Pfizer Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 13, 2026, 10:39 AM EDT - 9 days ago

Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines

Sep 10, 2026, 6:02 PM EDT - 12 days ago

Here are the stocks to favor in the fourth quarter — and those you should avoid

AAPL ABT ADBE AMZN AVGO BAC BMY

Sep 2, 2026, 9:00 AM EDT - 20 days ago

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

XRAY

Aug 31, 2026, 1:20 PM EDT - 22 days ago

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

LLY NVO TAK

Aug 31, 2026, 12:09 PM EDT - 22 days ago

Trump administration to announce drug pricing deals

AMGN LLY TAK

Aug 27, 2026, 5:48 PM EDT - 26 days ago

US FDA approves updated COVID vaccines for 2026-27 season

MRNA NVAX SNY BNTX

Aug 27, 2026, 4:30 PM EDT - 26 days ago

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

BNTX

Aug 26, 2026, 12:48 PM EDT - 27 days ago

White House to announce new drug pricing deals with biotechs, Bloomberg News reports

AMGN LLY

Aug 14, 2026, 1:45 PM EDT - 5 weeks ago

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Aug 14, 2026, 11:46 AM EDT - 5 weeks ago

Closed Pfizer biopharma facility in Everett gets a new lease on life

Aug 14, 2026, 11:11 AM EDT - 5 weeks ago

Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money

Aug 14, 2026, 1:00 AM EDT - 5 weeks ago

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

VALN

Aug 4, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 7:24 AM EDT - 7 weeks ago

Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:13 AM EDT - 7 weeks ago

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Aug 4, 2026, 7:12 AM EDT - 7 weeks ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

BNTX

Aug 4, 2026, 6:52 AM EDT - 7 weeks ago

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Aug 4, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Jul 30, 2026, 7:48 AM EDT - 7 weeks ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Jul 30, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Jul 29, 2026, 4:30 PM EDT - 7 weeks ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BNTX

Jul 22, 2026, 4:48 PM EDT - 2 months ago

Pfizer's prostate cancer drug combination gets US FDA priority review

Jul 22, 2026, 4:30 PM EDT - 2 months ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Jul 21, 2026, 7:10 PM EDT - 2 months ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY

Jul 16, 2026, 1:39 PM EDT - 2 months ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 10, 2026, 11:23 AM EDT - 2 months ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 6, 2026, 10:00 AM EDT - 2 months ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jun 29, 2026, 4:43 PM EDT - 2 months ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Jun 29, 2026, 1:20 AM EDT - 2 months ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 24, 2026, 3:52 PM EDT - 3 months ago

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 2:10 PM EDT - 3 months ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 10:51 AM EDT - 3 months ago

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 23, 2026, 12:10 PM EDT - 3 months ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 10:00 AM EDT - 3 months ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 22, 2026, 4:43 PM EDT - 3 months ago

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:30 PM EDT - 3 months ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 2:32 PM EDT - 3 months ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Jun 18, 2026, 6:52 AM EDT - 3 months ago

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:45 AM EDT - 3 months ago

Pfizer Announces Chief Financial Officer Transition

Jun 10, 2026, 7:56 AM EDT - 3 months ago

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 9, 2026, 2:07 PM EDT - 3 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Jun 9, 2026, 9:20 AM EDT - 3 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

Jun 9, 2026, 3:20 AM EDT - 3 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 6:49 AM EDT - 3 months ago

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:45 AM EDT - 3 months ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 6, 2026, 11:00 AM EDT - 3 months ago

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 3 months ago

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 3 months ago

Pfizer Press release: Study update

Jun 6, 2026, 9:06 AM EDT - 3 months ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:00 AM EDT - 3 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

La_Parka3 Sep. 23 at 2:48 AM

$MRNA $PFE Imagine shorting a biotech stock but all they know is MAHA, nonsensical buzzwords, and conspiratorial concepts that aren’t even connected to the sector.

0 · Reply

cmhuff Sep. 23 at 12:25 AM

$PFE Pretty happy here. Holding well enough, paying a nice dividend, and selling covered calls above my average for a few extra percent.

0 · Reply

DefenseMania Sep. 22 at 11:09 PM

$AMGN buying this at .34 in 1989 !!! $NVS $GILD $PFE

0 · Reply

mr_kO1 Sep. 22 at 6:30 PM

$PFE $PFE 🆙 80%

0 · Reply

bullman_is_back Sep. 22 at 5:41 PM

$VKTX $PFE takeout candidate?!

2 · Reply

SellasgpsCurativeBAT11 Sep. 22 at 4:10 PM

0 · Reply

truthseeeker Sep. 22 at 4:10 PM

1 · Reply

SellasgpsCurativeBAT11 Sep. 22 at 4:01 PM

0 · Reply

SellasgpsCurativeBAT11 Sep. 22 at 3:51 PM

0 · Reply

sam92 Sep. 22 at 3:24 PM

$PFE $SPSIPH $DJUSPR PFE Finally well deserved turnaround starting ! $ $ $ $ $ $ $ $ https://www.tradingview.com/chart/bor9VVk1/?symbol=NASDAQ%3AGRML

0 · Reply

HoneyButter Sep. 22 at 2:25 PM

$VKTX the real play here is as an acquisition target. $MRK or $PFE are the most likely. For a mere $7-10 billion they get a drug that has best in class weight loss, orally available, well tolerated, weight loss is immediate out the gate, and transitions to monthly maintenance. Whomever acquires this company is immediately in the game.

3 · Reply

PAHANA Sep. 22 at 2:16 PM

$PFE Revenue is down 2% YoY while $NVO revenue is up 6% YoY yeah stupid

0 · Reply

focafoca99 Sep. 22 at 2:15 PM

$PFE opens webcast registration for its November 3 analyst call. https://www.rapidticker.com/news/pfe-pfizer-invites-public-to-view-f60b9c

0 · Reply

La_Parka3 Sep. 22 at 2:01 PM

$MRNA $PFE Again, don’t say I didn’t warn the shorts that the Illuminati, the Freemasons, the Rothschilds, the World Economic Forum, and the New World Order have an agenda, and they have the longs’ backs. 🤣🤣🤣 I posted this a week ago. More pain to come for the shorts. And a big thank you to all the groups above for taking such good care of my investment.

0 · Reply

mrtallman Sep. 22 at 1:44 PM

$PFE ticker FLNA will double today. Drug study resumed

0 · Reply

DefenseMania Sep. 22 at 1:15 PM

$AMGN $LLY $PFE $ABBV https://finance.yahoo.com/healthcare/articles/amgen-announces-positive-topline-phase-130000414.html

0 · Reply

biolover Sep. 22 at 1:12 PM

$VKTX vs $PFE

0 · Reply

UnKnownWall Sep. 22 at 12:57 PM

$VKTX $VKTX maintenance trial, 98% kept their loss-weight on every other week, 90% kept their loss-weight on monthly dose !!! $LLY $NVO $PFE $MRK and big pharms now time to offer your price. Expect the news of offering and tomorrow BL Forum. Brian has to say nice words

0 · Reply

TopShelfStock Sep. 22 at 12:51 PM

$NVAX $NVAX The opening bell is ringing here at 8:30 AM Central Time and the setup is looking PHENOMENAL. 🔔🔥 Don't lose sight of the big picture today. Novavax is completely evolving into a high-margin biotech powerhouse. The chart is screaming bullish, holding beautifully above the 20-day and 50-day EMAs on surging volume. 📈 Smart money is laser-focused on two massive, game-changing fundamental catalysts right around the corner: The Pfizer Factor: $PFE has locked in their disease target. The second clinical trials are officially initiated, a massive $70M cash milestone is unlocked. 💰 The Oncology Revolution: Preclinical data drop expected in the coming quarters showing Matrix-M turning "cold" tumors "hot" to shrink them. 🔬 The platform pivot is real, the revenue runway is secured into the 2030s, and the tape is ready to squeeze.Let's smash through resistance today, bulls. Hold tight! 💎🙌🚀 #OpeningBell #BioTech #Breakout

1 · Reply

biolover Sep. 22 at 12:43 PM

$VKTX That is $PFE $10 B drug performance at wk 28 wt loss (12% despite wkly doses and flattening of curve vs 22% at $VKTX 33 wks ) and look at vomit rate in the monthly maintenance in vesper 1 after wk 28

0 · Reply

TheUnmaker Sep. 22 at 12:40 PM

$TNXP $GRAL $PFE $VKTX

0 · Reply

TopShelfStock Sep. 22 at 12:26 PM

$NVAX Good morning, $NVAX bulls! ☀️ Let’s get after it today. Chart is looking beautiful as we trade strong above the 20-day and 50-day EMAs on rising volume. 📈 The technical breakout is aligning perfectly with the massive fundamental shift. Don't lose sight of what's ahead:🚀 $70M Pfizer Milestone: $PFE has chosen their target. The second clinical trials launch, that cash is triggered.🔬 Oncology Pivot: Game-changing data on Matrix-M shrinking tumors expected in the coming quarters. Shaking off the macro noise and moving toward a high-margin future. Have a great trading day, everyone! Let's squeeze higher. 💎🚀 #BioTech #Investing

0 · Reply

Market Cap	158.11B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	9.07
Forward PE	9.29
Profit Margin	12.42%
Debt to Equity Ratio	0.74

Volume	26,669,200
Avg Vol	37,172,895
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	72%
Beta	0.34
Analysts	Sell
Price Target	$28.92